“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial of chemotherapy and everolimus for HER2 breast cancer that had spread outside the breast (BOLERO 1)
This trial looked at chemotherapy and everolimus for breast cancer that was HER2 positive. It was for women:
- whose breast cancer had grown into surrounding tissue (locally advanced) or had spread to elsewhere in the body
- who had not yet had any treatment for advanced breast cancer
More about this trial
Some breast cancers have large amounts of a protein called
It is usual to have Herceptin with chemotherapy. Paclitaxel is one of the chemotherapy drugs commonly used.
Sometimes a drug can stop working, even though the cancer responded to it at first. This is called resistance. In this trial, researchers wanted to find ways of treating breast cancer that had become resistant to Herceptin. They thought a drug called everolimus might help.
Everolimus is a type of
The aim of the trial was to see if having everolimus with Herceptin and paclitaxel helped women with HER2 positive breast cancer that had spread outside the breast.
Summary of results
The trial team found that having everolimus with Herceptin and paclitaxel was safe. But, it didn’t make a difference to how long it took for advanced HER2 positive breast cancer to get worse (progress).
719 women took part in the trial. They were put into 1 of 2 groups at random and were 2 times more likely to have everolimus than the dummy drug.
- 480 had everolimus tablets every day
- 239 had a dummy drug (
Everybody also had Herceptin and paclitaxel.
The study team followed the women up for an average of 3 ½ years. They looked at how long the women lived for after treatment without their cancer getting worse. This is called progression free survival. They found no difference between the 2 groups.
208 women had cancer that was HER2 positive but didn’t have receptors for oestrogen or progesterone. This is hormone receptor negative cancer. The researchers looked at progression free survival in this sub group. They found this was:
- 20.7 months in the group who had everolimus
- 13 months in the group who had the dummy drug
The difference between the 2 groups is not statistically significant. This means it could have happened by chance. However the trial team think that these findings might be worth looking at in a future trial.
Everyone had problems with hair loss and diarrhoea. The more serious side effects of everolimus included:
- a drop in the number of red and white blood cells
- painful mouth and lips (stomatitis)
The trial team found that having everolimus alongside Herceptin and paclitaxel wasn’t a useful treatment for advanced HER2 positive breast cancer.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Charles Swanton
NIHR Clinical Research Network: Cancer